Pfizer celebrates a year of achievements in 2015 annual review

PfizerPfizer Inc. (NYSE: PFE) has released its 2015 integrated annual review, an in-depth look into the company's financial, social and environmental performance. 2015 was marked by breakthrough scientific research, collaborations and partnerships. In the review, the scientists, researchers and business leaders offer in-depth looks at their projects and how they are working to discover and develop potential new medicines and vaccines to improve patient health.

"Our purpose at Pfizer is to bring therapies to patients that significantly improve their lives," said Pfizer Chairman and Chief Executive Officer Ian C. Read. "Thanks to the more than 97,000 Pfizer colleagues around the world, we met our yearly commitments and continued to build the company's capabilities toward our goal to become the world's premier, innovative biopharmaceutical company by the end of this decade."

As a result of our research as well as innovative collaborations with our peers and research partners, we saw great scientific progress across multiple therapeutic areas in 2015.

  • We advanced 39 potential new therapies in our R&D pipeline, representing the strongest progress in Pfizer's history.
  • Our research efforts in oncology have resulted in a broad and deep portfolio of compounds, including five immuno-oncology assets in human studies that have the potential to address the urgent therapeutic needs of cancer patients.
  • We advanced our investigational vaccines pipeline to research some of the most deadly infectious diseases that affect people of all ages.

In 2015, Pfizer made great strides to help ensure patients around the world have access to the Pfizer medicines and vaccines that are approved and available. "Our very license to operate depends on ensuring the medicines we make to improve patient health and wellbeing are available to as many people as possible," commented Sally Susman, Executive Vice President, Corporate Affairs. "Patient assistance is not a program or catchphrase, it is a commitment."

  • In 2015, we significantly expanded the eligibility of our U.S. patient assistance program, Pfizer RxPathways®. The program helped more than 250,000 people access our medicines during the year.
  • We continued global health partnerships including the International Trachoma Initiative at The Task Force for Global Health, which seeks to eliminate the world's leading cause of preventable blindness and marked 2015 with the 500 millionth dose donation of antibiotic Zithromax® (azithromycin).
  • 2015 was the 5th year of our partnership with Gavi, the Vaccine Alliance, in which we have pledged 740M doses of pneumococcal vaccines to immunize children in GAVI countries through 2025.
  • To address family planning needs of women in the developing world, our collaboration with the Bill & Melinda Gates Foundation and the Children's Investment Fund Foundation (CIFF) completed its first-full year, and was successful in helping broaden access to injectable contraceptive, Sayana® Press (medroxyprogesterone acetate), to tens of thousands of women across several countries in Africa and Asia.

Pfizer Inc.: Working together for a healthier world®
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of healthcare products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer healthcare products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.

Most Popular Now

Top 20 breaking World Pharma News of 2017

We are proud to announce the top 20 most popular breaking World Pharma News from 2017. Have a wonderful 2018 new(s) year filled with health, happiness, and spectacular su...

Novartis advances head-to-head superiority trials …

Novartis announced today the initiation of SURPASS, a head-to-head clinical trial of Cosentyx® (secukinumab) versus proposed biosimilar adalimumab** in ankylosing spondyl...

New research paper shows that AstraZeneca has achi…

In a research paper published today by Nature Reviews Drug Discovery(1), AstraZeneca's IMED Biotech Unit documents a more than four-fold improvement in R&D productivity f...

Diabetes drug 'significantly reverses memory loss…

A drug developed for diabetes could be used to treat Alzheimer's after scientists found it "significantly reversed memory loss" in mice through a triple method of action...

Sandoz regulatory submission for proposed biosimil…

Sandoz, a Novartis division and the global leader in biosimilar medicines, announced today that the US Food and Drug Administration (FDA) has accepted its Biologics Licen...

Zika remains a research and public health challeng…

Since 2016, when Zika was declared by the World Health Organization as a public health emergency of international concern, the virus has become established in more than 8...

Dirt-dwelling microbe produces potential anti-mela…

A type of soil-dwelling bacterium produces molecules that induce death in melanoma cells, research at Oregon State University shows. The molecule is a secondary metabolit...

Try exercise to improve memory, thinking

For patients with mild cognitive impairment, don't be surprised if your health care provider prescribes exercise rather than medication. A new guideline for medical pract...

FDA approves first treatment for breast cancer wit…

The U.S. Food and Drug Administration today expanded the approved use of Lynparza (olaparib tablets) to include the treatment of patients with certain types of breast can...

Novartis Kisqali® received FDA Breakthrough Therap…

Novartis today announced Kisqali® (ribociclib) received US Food and Drug Administration (FDA) Breakthrough Therapy designation for initial endocrine-based treatment of pr...

Novartis appoints Elizabeth Barrett as Oncology He…

Novartis announced today that Elizabeth (Liz) Barrett, currently Global President Oncology at Pfizer, Inc., has been appointed CEO Novartis Oncology and a member of the E...

Berry gives boost to cervical cancer therapy

According to the Centers for Disease Control and Prevention, approximately 12,000 women in the United States are diagnosed with cervical cancer each year. One of the most...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]